Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

October 2010 - FRMC

Department
10/28/2010
Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) is a combination product for the treatment of hypertension.
Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) is a combination product for the treatment of hypertension.
Tribenzor (olmesartan medoxomil,...
10/28/2010
First Report Managed Care
Feature
10/28/2010

Tim Casey

Tim Casey
Stockholm—A multinational, placebo-controlled phase 3 study found that a fasting C-peptide level >0.1 nmol/L could reasonably determine residual beta-cell function in patients with new-onset type 1 diabetes mellitus (T1DM). In addition, a...
Stockholm—A multinational, placebo-controlled phase 3 study found that a fasting C-peptide level >0.1 nmol/L could reasonably determine residual beta-cell function in patients with new-onset type 1 diabetes mellitus (T1DM). In addition, a...
Stockholm—A multinational,...
10/28/2010
First Report Managed Care
Feature
10/21/2010

Tim Casey

Tim Casey
Stockholm—A multicenter, randomized, double-blind, placebo-controlled, parallel-group study found that combining linagliptin treatment with a sulfonylurea (SU) in diabetic patients was well tolerated and produced statistically significant and...
Stockholm—A multicenter, randomized, double-blind, placebo-controlled, parallel-group study found that combining linagliptin treatment with a sulfonylurea (SU) in diabetic patients was well tolerated and produced statistically significant and...
Stockholm—A multicenter,...
10/21/2010
First Report Managed Care

Department

News Connection
10/21/2010

Tim Casey

Tim Casey
Advocates are pushing the White House and Congress to understand the severity of dementia and fund research to find treatments and a potential cure.
Advocates are pushing the White House and Congress to understand the severity of dementia and fund research to find treatments and a potential cure.
Advocates are pushing the White...
10/21/2010
First Report Managed Care
News Connection
10/21/2010

Tim Casey

Tim Casey
Leading up to the November elections, the political parties spent countless hours and millions of dollars debating the merits of the Patient Protection and Affordable Care Act (HR 3590). 
Leading up to the November elections, the political parties spent countless hours and millions of dollars debating the merits of the Patient Protection and Affordable Care Act (HR 3590). 
Leading up to the November...
10/21/2010
First Report Managed Care

Advertisement

Advertisement

Advertisement